Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus
Authors
Keywords
-
Journal
Diabetology & Metabolic Syndrome
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-14
DOI
10.1186/s13098-022-00797-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
- (2020) Jianhong Zhu et al. Lancet Diabetes & Endocrinology
- Application of blood pre-albumin and NT-pro BNP levels in evaluating prognosis of elderly chronic heart failure patients
- (2020) Linying Shi et al. Experimental and Therapeutic Medicine
- Effects of Dapagliflozin vs. Vildagliptin on Cardiometabolic Parameters in Diabetic Patients with Coronary Artery Disease: A Randomised Study
- (2019) A. Phrommintikul et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine
- (2019) Cao et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment
- (2019) Momir Mikov et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Thiazolidinediones: the Forgotten Diabetes Medications
- (2019) Harold E. Lebovitz Current Diabetes Reports
- Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial
- (2018) Petr Jarolim et al. DIABETES CARE
- Involvement of brain natriuretic peptide signaling pathway in the cardioprotective action of sitagliptin
- (2018) Samah S. Abbas et al. Pharmacological Reports
- Liraglutide relieves cardiac dilated function than DPP-4 inhibitors
- (2018) Takeyuki Hiramatsu et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials
- (2016) Islam Y. Elgendy et al. American Journal of Cardiovascular Drugs
- Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study
- (2016) Huang-Tz Ou et al. Cardiovascular Diabetology
- Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
- (2016) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan
- (2016) Chia-Hsuin Chang et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis
- (2016) Haruya Kawase et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1)
- (2016) Hiroshi Nomoto et al. PLoS One
- Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
- (2015) Hiroki Oe et al. Cardiovascular Diabetology
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events
- (2015) Risto Kerkelä et al. Journal of the American Heart Association
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- Dipeptidyl‐Peptidase 4 Inhibition and the Vascular Effects of Glucagon‐like Peptide‐1 and Brain Natriuretic Peptide in the Human Forearm
- (2014) Jessica K. Devin et al. Journal of the American Heart Association
- N-Terminal Probrain Natriuretic Peptide Is a Stronger Predictor of Cardiovascular Mortality Than C-Reactive Protein and Albumin Excretion Rate in Elderly Patients With Type 2 Diabetes
- (2013) Graziella Bruno et al. DIABETES CARE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of DPP4 Activity in Cardiovascular Districts: In Vivo and In Vitro Evidence
- (2013) L. Pala et al. Journal of Diabetes Research
- Renal and Cardiac Effects of DPP-4 Inhibitors from Preclinical Development to Clinical Research
- (2012) Berthold Hocher et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure
- (2011) Nelson Gomez et al. EUROPEAN JOURNAL OF HEART FAILURE
- DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion
- (2011) Hui-Chun Ku et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts
- (2010) Brenda K. Huntley et al. JOURNAL OF CELLULAR PHYSIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started